IgG / LG / Hurvitz SA / IgG4 / VL / VH / Cox / cImmunotherapy Laboratory / Hess / HP / /
Country
Switzerland / Netherlands / /
Currency
pence / / /
Event
FDA Phase / /
Facility
The Rockefeller University / stable bispecific IgG1 / University Medical Center / /
IndustryTerm
end products / cancer therapy / reagents/analytic tools / end product / Cancer Treat / bsIgG1 end product / large-scale antibody manufacturing / large-scale manufacturing / manufacturing scale / treatment of HER2-positive breast cancer / antigen-combining site / manufacturing / polypeptide chain / bsAb product / light chain / bench-scale protocol / /
MedicalCondition
rst-dose cytokine-release syndrome / Clin Prostate Cancer / certain diseases / HER2positive tumor / NCI-N87 gastric carcinoma / metastatic breast cancer / mg/kg bsIgG1-N297Q-CD3xHER2169 Tumor / release syndrome / Labrijn et al. dissociation / MS / hormone-refractory prostate cancer / Dissociation / HER2-positive tumors / tumor / non-Hodgkin lymphomas / cancer / NCI-N87 tumors / tumors / disease / NCI-N87 human gastric cancer / established NCI-N87 tumors / mean tumor / SCID / HER2-positive breast cancer / HER2-positive tumor / experimental vaginal candidiasis / /
MedicalTreatment
adoptive transfer / chemotherapy / immunotherapy / cancer therapy / antibody therapy / /
MusicGroup
A.F. / /
Organization
University Medical Center / U.S. Securities and Exchange Commission / Rockefeller University / New York / African Union / /
Person
Lewis Phillips / Brooklyn Park / Janine Schuurmana / Aran F. Labrijna / Joyce I. Meestersa / Muriel D. van Kampena / Kristin Strumanea / Michael J. Gramerb / Patrick H. C. van Berkela / Ewald T. J. van den Bremera / Sandra Verploegena / /
Position
human IgG1 backbone containing Author / representative / /
Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange Aran F. Labrijna, Joyce I. Meestersa, Bart E. C. G. de Goeija, Ewald T. J. van den Bremera, Joost Neijssena, Muriel D. van Kampena, Kristin